1
Biomarker Validation Following Sargramostim Treatment in Parkinson’s Disease
Condition(s):Parkinson’s Disease and ParkinsonismLast Updated:January 10, 2023Not yet recruiting
Sargramostim: 759 Clinical Trials, Page 1 of 76
Hide Studies Not Open or Pending
2
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
Condition(s):Solid Tumor; Solid Tumor, AdultLast Updated:December 2, 2022Suspended
3
Study of Sargramostim in Patients With COVID-19
Condition(s):COVID-19; SARS-CoV-2Last Updated:February 18, 2022Completed
4
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease
Condition(s):Alzheimer DiseaseLast Updated:July 21, 2022Recruiting
5
Sargramostim Use in COVID-19 to Recover Patient Health
Condition(s):Covid19; SARS-CoV InfectionLast Updated:February 6, 2023Completed
6
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Condition(s):Autoimmune Pulmonary Alveolar ProteinosisLast Updated:August 3, 2021Completed
7
Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Condition(s):Down SyndromeLast Updated:November 14, 2022Not yet recruiting
8
Sargramostim for Myeloid Dendritic Cell Deficiency
Condition(s):Kidney Diseases; Kidney TransplantLast Updated:December 31, 2018Terminated
9
Sargramostim (GM-CSF) + PD-1
Condition(s):Unresectable Melanoma; Metastatic Melanoma; Stage III Melanoma; Stage IV MelanomaLast Updated:October 13, 2022Recruiting
10
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
Condition(s):Drug Kinetics; Drug Effects on PhysiologyLast Updated:October 3, 2022Completed